Financings Of The Fortnight Ponders The Meaning Of The Best Year For Biotech IPOs Since 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by Regulus, Aragon, Antabio and Asceneuron.
You may also be interested in...
With New Data For A Drug In Dispute, Aragon Raises $50 Million
The San Diego biotech’s Series D round will support continued development of a drug that Medivation claims was included in the same license that covered the recently approved prostate cancer drug Xtandi.
More And Better Biotech IPOs, But Step-Ups Still Lag
Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.
Merck KGAA Begins Transformation Effort By Closing Geneva Site
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.